Results · Apr-Jun 2026 · filed 14 Aug 2026
Godavari Drugs Q1 FY27 results
Sales grew 17% to ₹28 crore from ₹23.8 crore in Apr-Jun 2025.
Operating profit fell 13% to ₹2.5 crore, an operating margin of 9.0% (down 3.2 points from a year ago).
Net profit grew 7% to ₹1.1 crore from ₹1 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −16%, net profit −14%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 28.0 | 23.8 | +17% |
| Operating profit (EBITDA) | 2.5 | 2.9 | −13% |
| Operating margin | 9.0% | 12.2% | −3.2 pts |
| Net profit | 1.1 | 1.0 | +7% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 17 Aug 2026Submission Of Statement On Deviation Or Variation In Utilisation Of Funds For The Quarter Ended 30 June 2026
- 17 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Allotment
- 14 Aug 2026Submission Of Un-Audited Standalone Financial Results For The Quarter Ended As On June 30, 2026
- 14 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting Held On 14.08.2026
- 11 Aug 2026Update on board meeting
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.